ProKidney (PROK) Stock Price & Analysis
PROK Stock Chart & Stats
- Day’s Range
- MXN 24.86 - MXN 28.00
- 52-Week Range
- MXN 23.10 - MXN 57.10
- Previous Close
- MXN 28.50
- Volume
- 0
- Average Volume (3M)
- 8,081
- Market Cap
- MXN 7.36B
- Enterprise Value
- MXN 1.31B
- Total Cash (Recent Filing)
- MXN 181.56M
- Total Debt (Recent Filing)
- MXN 3.52M
- Price to Earnings (P/E)
- ―
- Beta
- -4.01
- Next Earnings
- Nov 16, 2026 (Est.)
- EPS Estimate
- -3.01
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Clinical Progress
Progress toward a Phase 3 readout indicates that rilparencel is advancing through a pivotal development stage. Continued enrollment keeps the program moving toward an important efficacy assessment and preserves the potential for a meaningful clinical and commercial milestone.
Regulatory Alignment
Agreement with the FDA on eGFR slope as a surrogate endpoint can streamline the path from clinical evidence to regulatory review. This alignment may reduce uncertainty around the pivotal program and improve the strategic value of successful trial results.
Low Leverage
Very low reported debt limits near-term interest and repayment pressure compared with a highly leveraged structure. Although the company remains loss-making, modest debt gives management more flexibility to direct available resources toward clinical development and operations.
Bears Say
Severe Cash Burn
Large and continuing cash outflows show that the business is not self-funding and has not moved toward breakeven. Sustained development spending will require substantial financing, making future operations dependent on access to external capital.
Weak Operating Economics
Minimal, volatile revenue provides little operating support relative to the company’s very large losses. The scale mismatch indicates that commercial economics are not yet established, leaving future financial performance highly dependent on clinical success and eventual product adoption.
Equity Financing And Dilution
The planned access to substantial equity financing reinforces the company’s need for external capital to fund operations and development. Issuing shares can strengthen liquidity, but it also creates potential dilution for existing holders and may remain relevant while cash burn persists.
ProKidney News
Buy Rating Reaffirmed on PROK as Rilparencel’s Phase 3 Prospects and 2029 Launch Path Support Unchanged $12 Price Target
Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on ProKidney, retaining the price target of $12.00. Joseph Pantginis has given his Buy rating due to a combination of
Analyst Maintains Sell on ProKidney Amid Single-Asset Risk and Long Path to 2028 BLA, Keeps $1 Price Target Below Market
ProKidney, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Dina Ramadane from Bank of America Securities reiterated a Sell rating on the stock and has
Trade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial Stability
Prokidney Corp. (PROK) has disclosed a new risk, in the Regulation category. ProKidney Corp. faces heightened uncertainty as evolving U.S. tariff and import/export regulations could disrupt its supply chains and
PROK FAQ
What was ProKidney’s price range in the past 12 months?
What is ProKidney’s market cap?
When is ProKidney’s upcoming earnings report date?
How were ProKidney’s earnings last quarter?
Is ProKidney overvalued?
Does ProKidney pay dividends?
What is ProKidney’s EPS estimate?
How many shares outstanding does ProKidney have?
What happened to ProKidney’s price movement after its last earnings report?
Which hedge fund is a major shareholder of ProKidney?
What is the TipRanks Smart Score and how is it calculated?
ProKidney Stock Smart Score
Company Description
ProKidney
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Bruce Culleton
- Employees
- 231
- Website
- www.prokidney.com
- Address
- 2000 Frontis Plaza Blvd., Winston-Salem, NC, 27103, US
ProKidney (PROK) Earnings & Revenues
PROK Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 1 | 16 |
| Technical Analysis | 5 | 1 | 4 |
| Moving Averages | 0 | 0 | 12 |
